Aromatic sulfone hydroxamic acids and their use as protease inhibitors
申请人:Freskos N. John
公开号:US20050101641A1
公开(公告)日:2005-05-12
This invention is directed to aromatic sulfone hydroxamic acids (including hydroxamates) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
AROMATIC SULFONE HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS
申请人:Pharmacia Corporation
公开号:EP1562928A1
公开(公告)日:2005-08-17
US6890928B2
申请人:——
公开号:US6890928B2
公开(公告)日:2005-05-10
[EN] AROMATIC SULFONE HYDROXAMATES AND THEIR USE AS PROTEASE INHIBITORS<br/>[FR] SULFONE HYDROXAMATES AROMATIQUES ET LEUR UTILISATION COMME INHIBITEURS DE LA PROTEASE
申请人:PHARMACIA CORP
公开号:WO2002092588A2
公开(公告)日:2002-11-21
This invention is directed to aromatic sulfone hydroxamates (also known as 'aromatic sulfone hydroxamic acids') and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as 'matrix metalloprotease' or 'MMP') activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.